Pharmaceutical Companies in Kala Amb: 2026 List of 49

Published 12 February 2023 · Fully revised 20 September 2026 · Darshan Singh, 23 years in pharmaceutical QA, QC and drug regulatory affairs

What changed for every Kala Amb unit between 2024 and 2026

If you last looked at this cluster before 2024, three things have moved underneath it. All three affect whether a company on the list below is a safe manufacturing partner.

1. Revised Schedule M is now the operative GMP standard

The Ministry of Health and Family Welfare substituted the whole of Schedule M to the Drugs Rules, 1945 by notification G.S.R. 922(E) dated 28 December 2023, retitling it Good Manufacturing Practices and Requirements of Premises, Plant and Equipment for Pharmaceutical Products.^[3] Manufacturers above ₹250 crore turnover had to comply first. Smaller units were given a route out: under G.S.R. 127(E) dated 11 February 2025 (the Drugs Amendment Rules, 2025), a manufacturer with turnover below ₹250 crore could apply to the Central Licence Approving Authority within three months, submitting an upgradation plan, and — if granted — have its deadline extended to 31 December 2025.^[4]

Note the two qualifiers that the industry commentary usually drops: the extension had to be applied for, and it had to be granted. It was never automatic. Most Kala Amb units are squarely inside the under-₹250-crore band, so for practical purposes every unit on the list below falls into one of three states: it applied and upgraded; it applied and has not finished; or it never applied at all.

2. Himachal’s enforcement drive has already closed units

Both reports are statewide. Neither breaks the figures down by cluster, so none of them can be attributed specifically to Kala Amb — the named cluster in the April report is Baddi-Barotiwala-Nalagarh. Treat these as the regulatory weather across Himachal, not as a count of Kala Amb closures.

3. Almost every ISO claim in circulation is now out of date

ISO published ISO 9001:2026, the sixth edition, on 16 September 2026, and withdrew ISO 9001:2015 on the same date.^[7][8] ISO 9001:2008 was withdrawn in 2015 and ISO 9001:2000 in 2010.^[8] That means a directory entry reading ISO 9001:2008 now cites a standard that has been dead for eleven years and is two editions behind. ISO’s own guidance is that certified organisations transition within the timeframe set by their certification cycle and should ask their certification body — so a current certificate against the 2015 edition is not automatically invalid, but a certificate against 2008 or 2000 certainly tells you nothing about the company today.^[7]

Directory: 49 pharmaceutical companies in Kala Amb

Search by company name, road or product type. Filter by what the unit says it does.

Scroll the table sideways on a phone. Establishment years reflect the most frequently cited figure in public directories and differ between sources.

How to verify a Kala Amb manufacturer before you contract

This is the part no aggregator listing gives you, and in 2026 it is the only part that protects you. Work through all four in order. If a supplier resists step 1 or step 2, stop there.

• 1. The licence
• 2. Schedule M status
• 3. Quality record
• 4. Certificates

What Kala Amb actually is, and the tax story that is usually told wrong

Kala Amb sits in Sirmaur district in southern Himachal Pradesh, on the Nahan road near the Haryana border, with the units clustered along Nahan Road, Suketi Road, Trilokpur Road and Sadhaura Road. The Department of Pharmaceuticals’ Survey of Pharma Clusters, published February 2023, lists Kala Amb, Sirmour as one of 118 pharmaceutical clusters across 19 states and union territories, and one of seven in Himachal Pradesh — the state accounting for 6% of India’s clusters.^[1]

The detail that matters commercially is that the benefit was always time-limited. Notification 50/2003 granted it for “a period not exceeding ten years from the date of publication of this notification in the Official Gazette or from the date of commencement of commercial production, whichever is later”, and only to new units that commenced commercial production on or after 7 January 2003, or existing units that expanded installed capacity by at least 25% after that date.^[2]

When GST replaced central excise on 1 July 2017, the area-based exemptions went with it. They were succeeded by the Scheme of Budgetary Support, which reimburses 58% of the CGST and 29% of the IGST paid in cash after input tax credit is used — and, critically, only for the residual part of that original ten-year window, not a fresh ten years.^[12]

So the practical position in 2026 is this: for a unit that started commercial production in the 2006 to 2012 window that dominates the table above, the ten-year clock has run out. The excise advantage is a historical explanation for why the cluster exists. It is not a benefit available to a company setting up in Kala Amb today, and any consultant who presents it as one is selling you a 2010 pitch. What remains real is the cluster effect itself: a dense supply base, a trained workforce, and packaging, testing and logistics vendors within a few kilometres.

Where the cluster’s technical depth sits

Filtering the directory above by capability gives a reasonable picture. Sterile products — dry and liquid injectables, eye drops, ear and nasal drops — are the most capital-intensive category here, and the units listing them include Vellinton Healthcare, GMT Pharma, Iskon Remedies, MMG Healthcare, Pushkar Pharma and Saitech. These sit under Form 28 rather than Form 25, and are the category where the Schedule M sterile-area requirements bite hardest. You can see the dosage forms Laafon Galaxy itself supplies in its own injectable range.

Softgels and nutraceuticals are a genuine Kala Amb speciality, with Elnova Pharma, Vidhyasha, Aqua Softgel, Advin and Indorama all listing softgel capacity. APIs and phytochemicals are thinner on the ground — Sarv Biolabs is the clearest example — and Ayurvedic and herbal manufacturing runs alongside the allopathic units, notably in the Orison group.

The earlier version of this page also named Pace Biotech, Saitech Medicare and Watran Pharmaceuticals as Kala Amb players. None appears in the directory, and at least one of those names is associated with Baddi rather than Kala Amb. They have been removed rather than carried forward unverified.

Third-party manufacturing and PCD franchise from Kala Amb

Two different commercial relationships get muddled constantly, so it is worth separating them before you approach anyone on the list.

Third-party or contract manufacturing means you own the brand and the market, and the Kala Amb unit makes the product to your specification under its licence and its Schedule M obligations. Your quality agreement, your batch release terms and your right to audit are the whole of your protection. Filtering the directory to “Third-party / contract” gives 17 units that list this model. If you want the mechanics of the arrangement itself — costing, minimum batch sizes, the documentation trail — that is covered in how third-party pharma manufacturing in India actually works.

PCD (Propaganda Cum Distribution) franchise is the reverse: the manufacturer owns the brand, and you take monopoly distribution rights for a territory. Eleven units in the table list PCD programmes. The questions that decide whether a PCD agreement is worth signing — territory definition, product list, pricing protection, promotional-input commitments — are set out on Laafon Galaxy’s own PCD franchise programme, run from Karnal, which is a useful reference for what a properly structured agreement contains even if you go on to sign with a Kala Amb company instead.

What this page got wrong before, and what changed

This article was first published on 12 February 2023 and last touched in August 2025. This revision corrects the following.

• The “excise free zone” was linked to the SEZ Act, 2005. Wrong instrument. Corrected to the area-based central excise exemption under Notification 50/2003-CE, with the ten-year limit and the GST-era budgetary support successor explained.
• The tax benefit was presented as a standing reason to manufacture in Kala Amb. It expired with the ten-year window for the units concerned. Now stated as history, not as an offer.
• “ISO 9001:2001” was listed for one unit. No such edition exists. Flagged in the table rather than silently deleted, because the underlying directory entry is what a reader will find elsewhere.
• “DCGI” and “FDA” were listed as certifications. Neither certifies manufacturers in that sense. Both flagged.
• Every ISO edition cited in the table is now withdrawn. ISO 9001:2026 was published on 16 September 2026. Flags added throughout.
• One company appeared under three names — Saitech Pharmaceuticals, Saitech Pharma and Saitech Medicare — and another as both Vellinton Healthcare and Vellinton Lifesciences. Normalised, with the variants kept searchable.
• Companies named in the prose were absent from the table. Pace Biotech, Saitech Medicare and Watran Pharmaceuticals removed as unverified for this cluster.
• There was no mention of revised Schedule M at all on a page about choosing an Indian manufacturer, two and a half years after G.S.R. 922(E) and nine months after the compliance deadline lapsed. That is the substantive addition in this revision.
• The listing was presented as fact. It is now explicitly labelled as self-declared and unaudited, because that is what it is.

Frequently asked questions

Related on Laafon

• Company and plant listings tagged Kala AmbIndividual units in this cluster with listing dossiers, updated as they come to market.
• CDSCO revised Schedule-M compliance dashboardCurrent status, notifications and guidance on the standard driving Himachal’s inspections.
• Revised Schedule M gap assessment toolkitA 272-point self-audit workbook if you are assessing a site rather than a supplier.
• Third-party pharma manufacturing in IndiaHow the contract, the costing and the documentation trail actually work.
• Pharma loan licence: Form 25A and 28AManufacture under your own licence in someone else’s plant, with the real statutory fees.
• Pharma plants for sale across IndiaVerified listings, including units in Himachal, if acquisition beats contracting.
• Pharma plant setup cost calculatorLand, construction, machinery and section-wise capital estimates before you commit.

References

1. [1] Centre for Market Research and Social Development. Final Report — Survey of Pharma Clusters. New Delhi: Government of India, Ministry of Chemicals and Fertilizers, Department of Pharmaceuticals; February 2023. Table 3.3, State/UT wise locations of the pharma clusters. Available from: https://pharma-dept.gov.in/sites/default/files/Final%20Report-Survey%20of%20Pharma%20Clusters.pdf. Accessed September 2026.
2. [2] Government of India, Ministry of Finance, Department of Revenue. Notification No. 50/2003-Central Excise, G.S.R. 471(E). New Delhi; 10 June 2003. Available from: https://taxguru.in/excise-duty/notification-50-2003central-excise-dated-10th-june2003.html. Accessed September 2026.
3. [3] Ministry of Health and Family Welfare, Department of Health and Family Welfare (India). Notification G.S.R. 922(E) — amendment of the Drugs Rules, 1945, substituting Schedule M as Good Manufacturing Practices and Requirements of Premises, Plant and Equipment for Pharmaceutical Products. The Gazette of India, Extraordinary, Part II, Section 3(i). New Delhi; 28 December 2023. Copy consulted: https://pharmadocx.com/wp-content/uploads/2024/01/Notified-Schedule-M-dt-28.12.2023-1.pdf. Accessed September 2026.
4. [4] Ministry of Health and Family Welfare (India). Drugs Amendment Rules, 2025, G.S.R. 127(E), gazette reference CG-DL-E-11022025-260908. New Delhi; 11 February 2025. Summarised at: https://cliniexperts.com/regulatory-update/extension-of-timeline-for-implementation-of-schedule-m-for-small-medium-manufacturers/. Accessed September 2026.
5. [5] Sharma A. Himachal: Schedule M enforcement bares pharma fault lines. The Tribune. Shimla; 16 January 2026. Available from: https://www.tribuneindia.com/news/himachal/schedule-m-enforcement-bares-pharma-fault-lines/. Accessed September 2026.
6. [6] Sharma A. Small pharma units in Himachal shut shop as revised Schedule M norms tighten compliance net. The Tribune. Solan; 11 April 2026. Available from: https://www.tribuneindia.com/news/himachal/small-pharma-units-in-himachal-shut-shop-as-revised-schedule-m-norms-tighten-compliance-net/. Accessed September 2026.
7. [7] International Organization for Standardization. ISO 9001:2026 Quality management systems — Requirements. 6th ed. Geneva: ISO; published 16 September 2026. Available from: https://www.iso.org/standard/9001. Accessed September 2026.
8. [8] International Organization for Standardization. ISO 9001:2015 Quality management systems — Requirements, lifecycle record (stage 95.99, withdrawn 16 September 2026; supersedes ISO 9001:2008, withdrawn 2015, and ISO 9001:2000, withdrawn 2010). Geneva: ISO. Available from: https://www.iso.org/standard/62085.html. Accessed September 2026.
9. [9] Drugs Control Licensing Authority, Himachal Pradesh. Services — application and licence form mapping (Form 24/25, 24A/25A, 24B/25B, 27/28, 27A/28A, 27B/28B). Available from: https://dcla.hp.gov.in/Web/Service. Accessed September 2026.
10. [10] Central Drugs Standard Control Organization, Directorate General of Health Services, Ministry of Health and Family Welfare (India). Public view of Not of Standard Quality drugs. Available from: https://cdscoonline.gov.in/CDSCO/viewPublicNSQDrug. Accessed September 2026.
11. [11] Central Drugs Standard Control Organization (India). Alerts — monthly CDSCO and State NSQ alerts and spurious drug lists. Available from: https://cdsco.gov.in/opencms/opencms/en/Alerts/. Accessed September 2026.
12. [12] Agrawal D, Shah A, Krishnan A. Area based central excise exemption gets budgetary support under GST. Khaitan and Co LLP; 13 October 2017. Available from: https://www.mondaq.com/india/sales-taxes-vat-gst/637128/area-based-central-excise-exemption-gets-budgetary-support-under-gst. Accessed September 2026. Secondary source; the underlying DIPP notification of 5 October 2017 could not be opened directly.

Disclaimer. This page is technical and educational content for pharmaceutical professionals. It is not medical, legal, investment or procurement advice. Company details, establishment years and certification claims are reproduced from public business directories and company self-declarations; they have not been audited or verified by Laafon Galaxy Pharmaceuticals, and inclusion is neither an endorsement nor a recommendation. Indian statutory instruments, pharmacopoeial texts and CDSCO positions change frequently — verify the current position with the Central Drugs Standard Control Organization, the Himachal Pradesh Drugs Control Licensing Authority, or qualified professional advice before relying on anything here for a commercial or regulatory decision.